Presentation is loading. Please wait.

Presentation is loading. Please wait.

Donna M. Hepper, MD, Peggy Wu, MD, Milan J. Anadkat, MD 

Published by Modified over 5 years ago

Similar presentations

Presentation on theme: "Donna M. Hepper, MD, Peggy Wu, MD, Milan J. Anadkat, MD "— Presentation transcript:

1 Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib 
Donna M. Hepper, MD, Peggy Wu, MD, Milan J. Anadkat, MD  Journal of the American Academy of Dermatology  Volume 64, Issue 5, Pages (May 2011) DOI: /j.jaad Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 A and B, Patient at presentation, with scalp erythema, pustules, and alopecia. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Punch biopsy specimens showing an increased number of telogen and catagen hairs with perifollicular chronic inflammation and perifollicular fibrosis consistent with a scarring alopecia. (Original magnifications: A, ×40; B, ×100.) Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Donna M. Hepper, MD, Peggy Wu, MD, Milan J. Anadkat, MD "

Similar presentations

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD 

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD 
Dolphin-to-human transmission of lobomycosis?

Dolphin-to-human transmission of lobomycosis?
Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh  Adam Ingraffea, BA, Kevin Donohue, MD, Caroline Wilkel, MD,

Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh  Adam Ingraffea, BA, Kevin Donohue, MD, Caroline Wilkel, MD,
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.
Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD 

Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Expression of PD-L1 in mastocytosis

Expression of PD-L1 in mastocytosis
Array of cutaneous adverse effects associated with sorafenib

Array of cutaneous adverse effects associated with sorafenib
“Arrow” sign: A rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors  Pai-Shan Cheng, MD, Feng-Jie Lai,

“Arrow” sign: A rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors  Pai-Shan Cheng, MD, Feng-Jie Lai,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin  Jennifer Lin, MD, Jason P.

Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin  Jennifer Lin, MD, Jason P.
Hypertrophic scars from surgical staples mimicking folliculitis

Hypertrophic scars from surgical staples mimicking folliculitis
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Permanent chemotherapy-induced alopecia: A review

Permanent chemotherapy-induced alopecia: A review
Clindamycin-induced Sweet syndrome

Clindamycin-induced Sweet syndrome
Ben Tallon, MBChB, Elizabeth Blanchard, MD, Lynne J. Goldberg, MD 

Ben Tallon, MBChB, Elizabeth Blanchard, MD, Lynne J. Goldberg, MD 
Ming Yang Bi, AB, Jonathan L. Curry, MD, Angela M

Ming Yang Bi, AB, Jonathan L. Curry, MD, Angela M
JAK inhibitors in dermatology: The promise of a new drug class

JAK inhibitors in dermatology: The promise of a new drug class
Jonathan E. Blume, MD, Howard L. Stoll, MD, Richard T. Cheney, MD 

Jonathan E. Blume, MD, Howard L. Stoll, MD, Richard T. Cheney, MD 

Similar presentations

Ads by Google